Pegilodecakin as Monotherapy or in Combination with anti‐PD‐1 or Tyrosine Kinase Inhibitor in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma: Final Results of Cohorts A, G, H and I of IVY Phase I Study

Interleukin (IL)‐10 has anti‐inflammatory and CD8+ T‐cell‐stimulating properties. Pegilodecakin (pegylated recombinant human IL‐10) induces intratumoral antigen‐specific CD8 + T‐cells and upregulates IFNγ and major histocompatibility complexes (MHC) I and II. Pegilodecakin has single‐agent activity with manageable toxicity in advanced renal cell carcinoma (aRCC) (data cutoff 24 March 2016). Pegilodecakin with pembrolizumab or nivolumab revealed clinical activity in aRCC (data cutoff 1 July 2018).